Intestinal fistula treatment sales will expand through 2036, with anticholinergic drugs holding a 26.3% share of the drug class segment in 2026. Oral administration leads with a 41.7% share. The market was valued at USD 29.8 billion in 2025, reaching USD 31.4 billion by 2026-end and USD 52.6 billion by 2036.